However, systemic delivery of EPO, which is the current clinical practice for anemia, did not consistently show effectiveness and safety in clinical trials of patients with stroke, probably because of the poor BBB penetration of EPO, which leads to the requirement of a high, but toxic, dose of EPO (Siren et al., 2001; Wang et al., 2004). This evidence concerns the gene EPO and anemia (phenotype).